Skip to main content
Journal of Pharmaceutical Analysis logoLink to Journal of Pharmaceutical Analysis
. 2022 Dec 21;12(6):937. doi: 10.1016/j.jpha.2022.11.001

Corrigendum to “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review” [J. Pharma. Anal. 11 (2021) 265–271]

Leonny Dwi Rizkita 1, Indwiani Astuti 1,
PMCID: PMC9770015  PMID: 36573113

Original statement in Section 3:

3. Host-pathogen interactions in SARS-CoV-2 infection

SARS-CoV-2 shares many of the same characteristics as most coronavirus family viruses, including a pleomorphic or spherical shaped capsid envelope 150–160 nm in size, a polycistronic mRNA with a 5′ cap and 3′ poly-A-tail, and an unsegmented, positive, single-stranded RNA genome (30 kb) [32–34]. SARS-CoV-2 has two large polyproteins, ORF1a and ORF1b; four structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N); and eight accessory proteins: ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8a, ORF8b, and ORF9b.

Corrected statement in Section 3:

3. Host-pathogen interactions in SARS-CoV-2 infection

SARS-CoV-2 shares many of the same characteristics as most coronavirus family viruses, including a pleomorphic or spherical shaped capsid envelope 150–160 nm in size, a polycistronic mRNA with a 5′ cap and 3′ poly-A-tail, and an unsegmented, positive, single-stranded RNA genome (30 kb) [32–34]. SARS-CoV-2 has two large polyproteins, ORF1a and ORF1b; four structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N); and some accessory proteins: ORF3a, ORF6, ORF7a, ORF7b, ORF8, and ORF10.

The authors regret to inform that the statement in our review paper regarding the eight accessory proteins of SARS-CoV-2 were wrong and correction has been made to support the current findings.

The authors would like to apologize for any inconvenience caused.


Articles from Journal of Pharmaceutical Analysis are provided here courtesy of Xi'an Jiaotong University

RESOURCES